Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally.
$271.72+1.46%
报价 2026-11-06
市值
$62.92B
EV
$58.84B
PE (TTM)
31.6x
预期 PE (FY2027)
21.6x
52 周区间距高点 0.0%
$182.50$271.72
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-06 | 1.1x | 11.97 → 14.08（1.2x） | 19.3 |
| FY+32029-06 | 1.2x | 11.97 → 15.59（1.3x） | 17.4 |
毛利率 4% · TTM 收入 $257752M · 基数 EPS 11.97（调整后）
电话会信号
辅助标签Q1 20272026-11-05
扩产上调指引盈利拐点
指引 上调
信心 4
分析师 4
“We are raising our non-GAAP diluted EPS guidance to a new range of $12.80-$13.00, up from our prior range of $12.40-$12.60.”
原文引用（3）
- 扩产：we are expanding 3PL and cold chain capacity through our new St. Louis facility
- 上调指引：we are pleased to raise our fiscal 2027 EPS guidance to $12.80-$13 from the previous range of $12.40-$12.60
- 盈利拐点：our operating income grew 17% to $1 billion, achieving that milestone in a quarter for the first time
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CAHCardinal Health, Inc. | $62.92B | +1.5% | +3.9% | 4.3% | 31.6x | 16.9x | 11.9x | |
| CORCencora, Inc. | $63.65B | -1.8% | +4.5% | 4.3% | 23.2x | 13.6x | 15.1x | |
| EWEdwards Lifesciences Corporation | $58.87B | +1.3% | +11.8% | 78.1% | 44.5x | 32.6x | 44.1x | GARP |
| BDXBecton, Dickinson and Company | $57.71B | -0.8% | +2.4% | 45.8% | 25.3x | 14.7x | 17.3x | |
| ARGXargenx SE | $57.54B | +3.6% | – | 89.9% | 38.2x | 39.0x | 58.5x | |
| AAgilent Technologies, Inc. | $49.28B | +1.7% | +6.1% | 26% | 27.1x | 23.0x | 39.3x | |
| VEEVVeeva Systems Inc. | $49.18B | -2.1% | +16.5% | 75% | 48.9x | 36.6x | 29.9x | |
| IQVIQVIA Holdings Inc. | $44.8B | +2.6% | +8.0% | 32.9% | 33.1x | 16.6x | 16.9x | |
| HLNHaleon plc | $40.19B | -0.1% | – | 61.8% | 21.8x | 14.3x | – | |
| 同行中位数 | – | – | +7.1% | 53.8% | 30.1x | 19.8x | 29.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q4 2026 | 2026-03-31 Q3 2026 | 2025-12-31 Q2 2026 | 2025-09-30 Q1 2026 | 2025-06-30 Q4 2025 | 2025-03-31 Q3 2025 | 2024-12-31 Q2 2025 | 2024-09-30 Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.86B | $60.94B | $65.44B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B |
| Gross Margin | 4.3% | 4.1% | 3.4% | 3.6% | 3.7% | 3.9% | 3.5% | 3.6% |
| Operating Margin | 1.1% | 0.8% | 1.1% | 1% | 0.7% | 1.3% | 1% | 1.1% |
| Net Income | $394M | $399M | $471M | $450M | $239M | $506M | $400M | $416M |
| Diluted EPS | 1.69 | 1.69 | 1.97 | 1.88 | 1 | 2.1 | 1.65 | 1.7 |
| Operating Cash Flow | $1.69B | $1.82B | $686M | $973M | $1.53B | $2.92B | $-400M | $-1.65B |